Cellectis (CLLS)
(Delayed Data from NSDQ)
$1.77 USD
-0.01 (-0.56%)
Updated Nov 6, 2024 03:59 PM ET
After-Market: $1.75 -0.02 (-1.13%) 7:58 PM ET
3-Hold of 5 3
B Value A Growth A Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$1.77 USD
-0.01 (-0.56%)
Updated Nov 6, 2024 03:59 PM ET
After-Market: $1.75 -0.02 (-1.13%) 7:58 PM ET
3-Hold of 5 3
B Value A Growth A Momentum A VGM
Zacks News
ImmunoGen Posts Wider-than-Expected Loss; Sales Down Y/Y
by Zacks Equity Research
ImmunoGen, Inc. (IMGN) reported a loss of 39 cents per share (excluding restructuring charge) in the three month transition period ended Dec 31, marginally wider than both the Zacks Consensus Estimate and the year-ago loss of 38 cents.
Valeant's (VRX) Plaque Psoriasis Drug Approved in the U.S.
by Zacks Equity Research
Valeant Pharmaceuticals (VRX) recently announced that the the FDA has approved its Biologic License Application (BLA) for Siliq (brodalumab) injection the treatment of moderate-to-severe plaque psoriasis in adult patients.
Acorda (ACOR) Reports Narrower-than-Expected Loss in Q4
by Zacks Equity Research
Acorda Therapeutics, Inc. (ACOR) reported loss of 7 cents per share in the fourth quarter of 2016 (including the impact of stock-based compensation expenses), narrower than the Zacks Consensus Estimate of a loss of 18 cents.
Ascendis (ASND) Catches Eye: Stock Gains 7.2% in Session
by Zacks Equity Research
Ascendis Pharma A/S (ASND) moved big last session, as its shares rose over 7% on the day.
Abeona Therapeutics (ABEO) Catches Eye: Stock Jumps 5.8%
by Zacks Equity Research
Abeona Therapeutics Inc.(ABEO) was a big mover last session, as the company saw its shares rise nearly 6% on the day.
Acorda (ACOR) Catches Eye: Stock Gains 20.8% in Session
by Zacks Equity Research
Acorda Therapeutics, Inc. (ACOR) moved big last session, as its shares rose almost 21% on the day.
Will Cellectis (CLLS) Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Cellectis SA (CLLS).
The Zacks Analyst Blog Highlights: Celgene, Cellectis S.A., Exelixis, Exact Sciences and Sunesis Pharmaceuticals
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Celgene, Cellectis S.A., Exelixis, Exact Sciences and Sunesis Pharmaceuticals
Cellectis (CLLS) Shows Strength: Stock Moves 9.1% Higher
by Zacks Equity Research
Cellectis S.A. (CLLS) shares rose over 9% in the last trading session.
Why Cellectis (CLLS) Stock Might be a Great Pick
by Zacks Equity Research
Cellectis (CLLS) in the Medical-Biomedical/Genetics space is seeing solid earnings estimate revision activity, and is a great company from a Zacks Industry Rank perspective.